On April 28, 2022 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) reported that management plans to report its first quarter 2022 financial results on Thursday, May 12, 2022, after the close of the U.S. financial markets (Press release, CTI BioPharma, APR 28, 2022, View Source [SID1234613138]). Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 7291915. A live audio webcast of the event may also be accessed through the "Investors" section of CTI’s website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

On April 28, 2022 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, reported a presentation outlining the design of its breast cancer vaccine trial at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held June 3-7, 2022 (Press release, Anixa Biosciences, APR 28, 2022, View Source [SID1234613155]). The presentation, titled "Phase 1 Trial of an alpha-Lactalbumin vaccine in patients with moderate- to high-risk operable triple-negative breast cancer (TNBC)" will be presented by the study’s principal investigator, Dr. George Thomas Budd of Cleveland Clinic, Anixa’s collaboration partner.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additional presentation details can be found below:

Abstract #: TPS1125

Date/Time: June 6, 2022, 9:00 AM EDT

About Triple-Negative Breast Cancer

One in eight women in the U.S. will be diagnosed with an invasive breast cancer at some point in their lives. Approximately 10-15% of those diagnoses are TNBC, however TNBC accounts for a disproportionately higher percentage of breast cancer deaths and has a higher rate of recurrence. This form of breast cancer is twice as likely to occur in African-American women, and approximately 70% to 80% of the breast tumors that occur in women with mutations in the BRCA1 genes are triple-negative breast cancer.

About Anixa Bioscience’s Breast Cancer Vaccine

Anixa’s investigational vaccine, currently in Phase 1 trials, takes advantage of endogenously produced proteins that have a function at certain times in life, but then become "retired" and disappear from the body. One such protein is a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues, but is present in the majority of triple-negative breast cancers. Activating the immune system against this "retired" protein provides preemptive immune protection against emerging breast tumors that express α-lactalbumin. The vaccine also contains an adjuvant that activates an innate immune response, which allows the immune system to mount a response against emerging tumors to prevent them from growing.

On April 28, 2022 Chimera Bioengineering reported that it has been selected as the winner of the Asian Fund for Cancer Research’s (AFCR) 2021 BRACE Award Venture Competition—a first-of-its-kind program for early stage oncology technology companies focused on Asian-prevalent cancers. Chimera is developing an innovative CAR-T cell therapy platform for conditional, location-specific activation to target solid tumors (Press release, Chimera Bioengineering, APR 28, 2022, View Source [SID1234613171]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a result of its win, Chimera received US$500,000 in investment from AFCR and additional investments from AFCR-syndicated co-investors, bringing in a total of US$7.5 million of new funds for the company. This follows a rigorous review and evaluation process performed by the BRACE program’s three blue ribbon Committees: Selection, Judging and Investment.

BRACE Award Venture Competition winners not only receive AFCR’s investments, but also feedback and validation from key opinion leaders in the life sciences field. Additionally, the BRACE program provides participating companies with connections and access to cancer experts within AFCR’s worldwide network, as well as amplification for visibility and publicity.

"We are excited to be named the winner of the 2021 BRACE Award Venture Competition, and are thrilled by the support we have received from new investors and the connections we have made to high-caliber advisors," stated Chimera Bioengineering Chief Scientific Officer and Co-Founder Gus Zeiner, Ph.D. "We greatly value the enhanced credibility and exposure from winning the 2021 BRACE Award Venture Competition and look forward to having AFCR being a part of our journey to provide transformative therapies for cancer patients in Asia and beyond."

"During the evaluation for AFCR’s BRACE Award, I was impressed with Chimera’s insightful approach of leveraging natural mechanisms to engineer T cells," said BRACE Award Venture Competition Selection and Judging Committee Co-Chair Raju Kucherlapati, Ph.D. "The company is developing a way to engineer these critical immune system cells to selectively activate when they encounter tumor cells and deliver a payload to counteract the suppressive tumor microenvironment."

"Furthermore, Chimera’s initial data in preclinical models provide support for the ability of their platform technology to apply the curative potential of CAR-T therapies to treating solid tumors," added Dr. Kucherlapati, the Paul C. Cabot Professor of Genetics at Harvard Medical School and co-founder of multiple successful biotechnology companies, including Millennium Pharmaceuticals.

"I am proud that interest in the BRACE Award Venture Competition has spread around the world, and it is being recognized as a valuable source of investment for early stage oncology companies," expressed Asian Fund for Cancer Research Chief Executive Officer and Founder Sujuan Ba, Ph.D. "Like the potentially transformative CAR-T technology being pursued by Chimera, AFCR’s BRACE Award Venture Competition is designed to accelerate the commercialization of innovative cancer research discoveries for cancer patients, in Asia and worldwide."

"The BRACE Award Venture Competition is an annual event to support promising early stage oncology start-ups that work on cancers prevalent in Asia," exclaimed Asian Fund for Cancer Research Chairman Lance Kawaguchi. "In addition to the investment into winners such as Chimera Bioengineering, AFCR brings to the company other valuable resources, such as access to the National Foundation for Cancer Research and AIM-HI Accelerator Fund, which are founding partners of the BRACE Award Venture Competition."

Learn more about the BRACE Award Venture Competition, including the 2022 iteration of the program, now in its fourth year, at View Source

About the BRACE Award Venture Competition

The annual Bridging Research from Academia to Cancer Entrepreneurship (BRACE) program, launched in 2019, is designed to accelerate the commercialization of innovative laboratory discoveries on cancers that are prevalent in Asia. BRACE Award Venture Competitions provide start-up companies with investment capital, visibility and access to a network of world-class key opinion leaders, life sciences industry experts, investors and entrepreneurs.

On April 28, 2022 Lunit reported the presentation of 11 abstracts featuring its AI-biomarker platform at the 2022 ASCO (Free ASCO Whitepaper) Annual Meeting from June 3 to 7 (Press release, Lunit, APR 28, 2022, View Source [SID1234613187]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Since 2019, the company has presented groundbreaking findings based on its AI-powered tissue analysis platform, ‘Lunit SCOPE.’ This year’s ASCO (Free ASCO Whitepaper) Meeting will showcase the largest number of studies by Lunit, including seven poster presentations and four online publications.

One of Lunit’s presentations will focus on the use of AI technology to define tumor immune phenotypes. Findings from the study validate the effectiveness of Lunit SCOPE IO—Lunit’s AI biomarker—in predicting clinical outcomes of immunotherapy across more than 16 different cancer types.

Lunit’s other major study assesses the practical efficacy of Lunit SCOPE PD-L1, an AI-powered PD-L1 tumor proportion score (TPS) analyzer, which recently has received a CE mark.

In addition, Lunit will also present clinical findings that demonstrate the accuracy of its AI imaging solution in detecting high-risk breast cancer patients.

The company’s four abstracts due to be published online include a joint study to evaluate the performance of ‘Lunit SCOPE HER2’ in reducing interobserver variation among pathologists, as well as an examination of the landscape of tumor-infiltrating lymphocytes (TIL) in neuroendocrine tumors, a rare form of cancer, by using Lunit SCOPE IO.

"Through several studies, Lunit has demonstrated the credibility of Lunit SCOPE IO as a practical biomarker to predict cancer patients’ response to immunotherapy," said Chan-Young Ock, Chief Medical Officer at Lunit. "This study validates the efficacy of our AI biomarker as we continue to expand the range of our research across all cancer types originating from the epithelium."

On April 28, 2022 ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, reported its abstracts were accepted for presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, June 3-7, in Chicago (Press release, ImmunityBio, APR 28, 2022, View Source [SID1234613122]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

QUILT 3.032 Oral Presentation: Principal Investigator Karim Chamie, M.D., Associate Professor of Urology at UCLA, will present final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary non-muscle-invasive bladder cancer (NMIBC).
QUILT 88 Poster Session: Phase 2 clinical trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.
ImmunityBio will be exhibiting at booth number 26135.